This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Researchers at the Heart Research Institute (HRI) have made a new discovery, finding an existing drug used to kill tumor cells in cancer patients could also be used to save the limbs of patients with blocked arteries in their legs.
Led by Mehdi Shishehbor DO, MPH, PhD, interventional cardiologist and a pioneer in the field of limb preservation, the Dodero Center will revolutionize care for patients at risk of losing a leg due to peripheralarterydisease and diabetes. For patients with no other options, amputation may become imminent.
Researchers have discovered that the smooth muscle cells that line the arteries of people with atherosclerosis can change into new cell types and develop traits similar to cancer that worsen the disease.
(MedPage Today) -- For patients with peripheralarterydisease (PAD) and chronic limb-threatening ischemia, drug-eluting stents and drug-coated balloons did not improve amputation-free survival compared with balloon angioplasty alone in the BASIL.
Given this dismal outcome, the prognosis of CLTI is worse than most cancers.3,4 The global burden of peripheralarterydisease. Decline in functional performance predicts later increased mobility loss and mortality in peripheralarterialdisease. The global burden of peripheralarterydisease.
Led by Mehdi Shishehbor DO, MPH, PhD, interventional cardiologist and a pioneer in the field of limb preservation, the Dodero Center will revolutionize care for patients at risk of losing a leg due to peripheralarterydisease and diabetes. For patients with no other options, amputation may become imminent.
The Shockwave E 8 catheter is designed to optimize the treatment of patients with calcified femoro-popliteal and below-the-knee peripheralarterydisease (PAD), including patients with complex chronic limb-threatening ischemia (CLTI). Food and Drug Administration (FDA).
13, 2024Sensome hasannounced positive results from two studies of its Clotild Smart Guidewire System demonstrating its ability to successfully identify fresh clot thrombus rich in red blood cells (RBCs) in peripheralarterydisease (PAD) and differentiate it from other tissue encountered during PAD procedures. Lancet Glob.
years of age, P <0.001), cerebral or peripheralarterydisease (6.2% It would be like diagnosing women with metastatic breast cancer, but finding that just as many women with metastatic breast cancer were alive in 5 years as women not diagnosed with breast cancer. versus 66.3%; P =0.004), older age (62.4±7.9
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content